Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
Studying Systemic lupus erythematosus
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- University of Bern
- Principal Investigator
- Sandra Bigi, PD MD, M.DISPM, University of Bern, Bern; Kinderspital Zentralschweiz, Luzern
- Enrollment
- 500 enrolled
- Eligibility
- 36 years · All sexes
- Timeline
- 2020 – 2071
Study locations (13)
- Kantonsspital Aarau, Aarau, Canton of Aargau, Switzerland
- Children's Hospital of Eastern Switzerland, Sankt Gallen, Canton of St. Gallen, Switzerland
- University Children's Hospital Lausanne (CHUV), Lausanne, Canton of Vaud, Switzerland
- Kantonsspital Winterthur, Winterthur, Canton of Zurich, Switzerland
- Pediatric Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Canton Ticino, Switzerland
- Kantonsspital Graubünden, Chur, Kanton Graubünden, Switzerland
- University Children's Hospital Basel, UKBB, Basel, Switzerland
- University Children's Hospital, Inselspital Bern, Bern, Switzerland
- Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- Hôpital Fribourgeois - Freiburger Spital, Fribourg, Switzerland
- University Hospitals of Geneva (HUG), Geneva, Switzerland
- Kinderspital Zentralschweiz, Lucerne, Switzerland
- University Children's Hospital Zurich, Zurich, Switzerland
Collaborators
Schweizerische Multiple Sklerose Gesellschaft · Insel Gruppe AG, University Hospital Bern · Novartis · Anna Mueller Grocholski-Stiftung · Gottfried und Julia Bangerter- Rhyner-Stiftung, Basel · Biogen · Roche Pharma (Switzerland) Ltd · Fondation Johanna Dürmüller-Bol · Kantonsspital Aarau · University Children's Hospital Basel · Ente Ospedaliero Cantonale, Bellinzona · Kantonsspital Graubünden · University Hospital, Geneva · Centre Hospitalier Universitaire Vaudois · Ostschweizer Kinderspital · Kantonsspital Winterthur KSW · Sanofi · Hôpital Fribourgeois · University Children's Hospital, Zurich · Luzerner Kantonsspital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05017142 on ClinicalTrials.govOther trials for Systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07107659Safety and Efficacy of ONT01 in LupusHospital for Special Surgery, New York
- RECRUITINGNANCT07558850Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune DiseasesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGNCT06948110Deciphering the Genetic Architecture of Autoimmune DiseasesNational Human Genome Research Institute (NHGRI)
- RECRUITINGPHASE2NCT07409181A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)Boehringer Ingelheim
- RECRUITINGPHASE3NCT07332481A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseEMD Serono Research & Development Institute, Inc.
- RECRUITINGEARLY PHASE1NCT07526350MTS109 in Patients With Refractory Autoimmune DiseasesShanghai Changzheng Hospital
- RECRUITINGEARLY PHASE1NCT07490041Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic DiseasesThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNANCT07470151Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology